444 At4 receptor/Insulin Regulated Aminopeptidase Deficiency Is Both Vaso- And Cardio-Protective Under Condition of Cardiovascular Stress in Mice

Gaspari, Tracey; Pong, W.Y.; Lee, H.W.; Welungoda, Iresha; Chai, Siew Yeen; Widdop, RE

doi:10.1097/01.hjh.0000420299.05272.fb

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This receptor, which was originally reported to colocalize with the glucose transporter GLUT‐4, has a role in the degradation of vasopressin and oxytocin. Ang IV inhibits the enzymatic activity of IRAP and knockout models and studies of non‐peptide inhibitors suggest a role of IRAP in cardiovascular disease, mainly in target‐organ damage (Gaspari et al, ; Vinh, Widdop, Chai, & Gaspari, ; Vinh, Widdop, Drummond, & Gaspari, ). On the other hand, there is the ACE 2/Ang 1–7/ mas receptor axis of the RAAS.…”

Section: Development Of Renin–angiotensin–aldosterone/mas Receptor Axismentioning

confidence: 99%

Angiotensin II‐induced micro RNA‐21 culprit for non‐small‐cell lung adenocarcinoma

Luan

Liu

Shi³

2019

Drug Development Research

View full text Add to dashboard Cite

Lung cancer is among the most complicated cancers, with an estimated 1.6 million deaths each year for both men and women. However, the proportion of lung cancer patients in developing nations has increased from 31% to 49.9% in the last two decades. There are two main subtypes of lung cancer, small‐cell lung carcinoma and non‐small‐cell lung carcinoma (NSCLC), accounting for 15% and 85% of all lung cancer, respectively. Adenocarcinoma is the most common type of lung cancer in smokers and nonsmokers in men and women regardless of their age. Chemicals in cigarette smoke and nicotine enter our bloodstream and can then affect the entire body and finally lead to the activation of several important, pro‐survival signaling pathways. The biologically active peptide of RAAS on overstimulation enhance Ang II mediates cell proliferation, fibrosis and inflammatory effects via AT1 receptor. Very few studies highlight the diagnostic and therapeutic potential of miRNAs with the EGFR‐regulated miRNA‐21.

show abstract

Section: Development Of Renin–angiotensin–aldosterone/mas Receptor Axismentioning

confidence: 99%

Angiotensin II‐induced micro RNA‐21 culprit for non‐small‐cell lung adenocarcinoma

Luan

Liu

Shi³

2019

Drug Development Research

View full text Add to dashboard Cite

show abstract

Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies

et al. 2021

View full text Add to dashboard Cite

The renin-angiotensin-aldosterone system (RAAS) is responsible for maintaining blood pressure and vascular tone. Modulation of the RAAS, therefore, interferes with essential cellular processes and leads to high blood pressure, oxidative stress, inflammation, fibrosis, and hypertrophy. Consequently, these conditions cause fatal cardiovascular and renal complications. Thus, the primary purpose of hypertension treatment is to diminish or inhibit overactivated RAAS. Currently available RAAS inhibitors have proven effective in reducing blood pressure; however, beyond hypertension, they have failed to treat end-target organ injury. In addition, RAAS inhibitors have some intolerable adverse effects, such as hyperkalemia and hypotension. These gaps in the available treatment for hypertension require further investigation of the development of safe and effective therapies. Current research is focused on the combination of existing and novel treatments that neutralize the angiotensin II type I (AT1) receptor-mediated action of the angiotensin II peptide. Preclinical studies of peptide- and nonpeptide-based therapeutic agents demonstrate their conspicuous impact on the treatment of cardiovascular diseases in animal models. In this review, we will discuss novel therapeutic agents being developed as RAAS inhibitors that show prominent effects in both preclinical and clinical studies. In addition, we will also highlight the need for improvement in the efficacy of existing drugs in the absence of new prominent antihypertensive drugs.

show abstract

Arterial Hypertension: Novel Pharmacological Targets and Future Perspectives

Popa,

Clim,

Pînzariu

et al. 2024

JCM

View full text Add to dashboard Cite

Arterial hypertension (HTN) is one of the major global contributors to cardiovascular diseases and premature mortality, particularly due to its impact on vital organs and the coexistence of various comorbidities such as chronic renal disease, diabetes, cerebrovascular diseases, and obesity. Regardless of the accessibility of several well-established pharmacological treatments, the percentage of patients achieving adequate blood pressure (BP) control is still significantly lower than recommended levels. Therefore, the pharmacological and non-pharmacological management of HTN is currently the major focus of healthcare systems. Various strategies are being applied, such as the development of new pharmacological agents that target different underlying physiopathological mechanisms or associated comorbidities. Additionally, a novel group of interventional techniques has emerged in recent years, specifically for situations when blood pressure is not properly controlled despite the use of multiple antihypertensives in maximum doses or when patients are unable to tolerate or desire not to receive antihypertensive medications. Nonetheless, reducing the focus on antihypertensive medication development by the pharmaceutical industry and increasing recognition of ineffective HTN control due to poor drug adherence demands ongoing research into alternative approaches to treatment. The aim of this review is to summarize the potential novel pharmacological targets for the treatment of arterial hypertension as well as the future perspectives of the treatment strategy.

show abstract

444 At4 receptor/Insulin Regulated Aminopeptidase Deficiency Is Both Vaso- And Cardio-Protective Under Condition of Cardiovascular Stress in Mice

Cited by 3 publications

References 0 publications

Angiotensin II‐induced micro RNA‐21 culprit for non‐small‐cell lung adenocarcinoma

Angiotensin II‐induced micro RNA‐21 culprit for non‐small‐cell lung adenocarcinoma

Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies

Arterial Hypertension: Novel Pharmacological Targets and Future Perspectives

Contact Info

Product

Resources

About